Elanco Animal Health (ELAN) is back in focus after securing USDA approval for its TruCan Ultra Lyme-L4 canine vaccine and outlining Elanco Ventures, a US$25 million venture platform targeting early stage animal health opportunities.

Against this backdrop of new products and the Elanco Ventures launch, Elanco Animal Health’s recent momentum has been positive, with a 30 day share price return of 6.79% and a 1 year total shareholder return of 70.42%, while the 5 year total shareholder return remains down 30.37%, highlighting a sharp recovery from earlier weakness.

If this kind of rebound catches your eye, it could be a good moment to see what else is setting up for potential growth across 39 healthcare AI stocks

With Elanco Animal Health trading at US$24.37 and shown at a 33.13% discount to one intrinsic value estimate and a 22.52% discount to analyst targets, is there still an attractive entry point here or is the market already pricing in future growth?

Most Popular Narrative: 18.2% Undervalued

Elanco Animal Health's most followed valuation narrative points to a fair value of $29.79 per share, compared with the recent close at $24.37. This puts the focus squarely on how future growth and margins might bridge that gap.

Operational focus on product launches and infrastructure optimization sets the stage for margin expansion from 2026 onwards, improving earnings. At the same time, geographic expansion and a diversified portfolio across pets and farm animals are expected to help the company maintain balanced revenue growth, supporting financial stability.

Curious what sits behind that fair value gap for Elanco Animal Health? The narrative leans heavily on revenue compounding, margin repair and a richer earnings multiple. Want to see exactly how those moving parts are stitched together into that $29.79 figure?

Result: Fair Value of $29.79 (UNDERVALUED)

However, Elanco Animal Health still carries execution and financial risks, including pressure on margins from higher operating expenses and the need to manage meaningful net leverage.

Next Steps

Given the mixed tone around Elanco Animal Health’s recovery and risks, it makes sense to review the underlying data yourself and decide quickly where you stand, then weigh those opinions against the 4 key rewards.

Looking for more investment ideas beyond Elanco Animal Health?

If Elanco Animal Health has sharpened your interest in what is possible, do not stop here. Broaden your watchlist and keep fresh ideas on your radar.

• Target potential mispricings by scanning companies our models flag as high quality yet out of favor via the 43 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that feature strong finances and dependable balance sheets in the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for underfollowed stories that still show solid fundamentals using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.